ARTICLES BY TYLER MENICHIELLO
-
![Telemedicine and human Liver recovery-GettyImages-1397378186]( "Growing Livers In Lymph Nodes, A Lesson On Working With Nature")
Growing Livers In Lymph Nodes, A Lesson On Working With Nature5/22/2024Dr. Michael Hufford, CEO of LyGenesis, believes in leveraging natural biology to develop cell therapies. Learn how the company’s doing so to grow ectopic livers inside patients with end-stage liver disease.
-
![goals planning 2024-GettyImages-1696762450]( "The Industry's Positive Outlook For ADCs In 2024")
The Industry's Positive Outlook For ADCs In 20242/26/2024Check out the results of DeciBio's Antibody-Drug Conjugates 2024 Industry Survey, which predict another bullish year for the growing modality.
-
![Antibody drug conjugates ADCs GettyImages-1715913285]( "2023 ADC Roundup: A Year Of Collaboration And Licensing Deals")
2023 ADC Roundup: A Year Of Collaboration And Licensing Deals1/3/2024Despite the continuation of a poor funding climate in biotech, 2023 was a big year for antibody-drug conjugates (ADCs).
-
![businessmen handskae-agreement-GettyImages-1483521942]( "Considerations For Licensing Platforms From Universities")
Considerations For Licensing Platforms From Universities6/16/2023Even the best platforms and technologies don’t come out of universities IND-ready. Just ask Coeptis Therapeutics, which recently licensed the novel CAR-T platform, SNAP-CAR, from the University of Pittsburgh. Coeptis’ Dave Mehalick, and Dan Yerace discuss the licensing agreement and the growing pains to expect when preparing a new platform for an IND.
Tyler Menichiello
Tyler Menichiello is a contributing editor to Bioprocess Online, Cell & Gene, and Clinical Leader. He interviews executives and subject matter experts across the biopharma industry to write about their successful approaches in biologics development from pre-IND planning all the way through trial design, manufacturing, and commercialization. He aims to investigate the industry’s most prevalent challenges and emerging best practices to provide both interesting and actionable content for industry leaders. Prior to writing for Life Science Connect, Tyler spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, where he worked on clinical trials involving hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can email Tyler at tyler.menichiello@lifescienceconnect.com, or visit his LinkedIn profile.